GLP-1 Maintenance Dosing: Staying on a Lower Dose Long-Term Instead of Stopping

The clinical consensus that GLP-1 drugs should be taken indefinitely — like antihypertensives — runs into a practical obstacle: full-dose continuation indefinitely is expensive and sometimes not tolerable at higher doses. Maintenance dosing is the evidence-based middle ground.

This article awaits medical-reviewer signoff.

The problem with stopping entirely

The weight regain data is clear: two-thirds of lost weight returns within 12 months of stopping semaglutide; 82% of tirzepatide patients regain more than 25% of their loss within one year. The body's defended weight set-point reasserts itself when the drug is removed.

Full cessation is the standard default when a patient cannot continue — but it produces near-certain large-scale regain for most patients.

What maintenance dosing provides

Maintenance dosing involves stepping down from the maximum therapeutic dose used during active weight loss to a lower dose, then continuing indefinitely at that lower level.

The rationale: even at a lower dose, some GLP-1 receptor agonism is maintained. The body is not in the "full drug removed" state that produces rapid regain. The appetite suppression and metabolic effects are reduced but not eliminated.

SURMOUNT-MAINTAIN trial (tirzepatide):

After an open-label period where patients reached weight-loss stabilisation on tirzepatide, participants were randomised to:

• Continue at maximum tolerated dose
• Step down to tirzepatide 5 mg
• Switch to placebo

At 52 weeks and 112 weeks:

The 5 mg maintenance group held approximately 16.6% vs 21.9% at max dose — roughly 76% of the maximum benefit. Compared to placebo (9.9%), the maintenance group preserved substantially more of their lost weight.

Cardiometabolic preservation: Blood pressure, HbA1c, waist circumference, and lipid improvements were maintained in the tirzepatide groups in proportion to the weight retained. The placebo group's cardiometabolic benefits reversed.

Semaglutide maintenance: the evidence gap

An equivalent randomised maintenance-dose trial for semaglutide — comparing a lower maintenance dose versus placebo after stabilisation — has not yet published results at the scale and design of SURMOUNT-MAINTAIN. The pharmacological reasoning is the same: any GLP-1 agonism above zero should provide more benefit than zero.

The tapering guide discusses the available semaglutide discontinuation data and the maintenance rationale in more detail.

When maintenance dosing makes clinical sense

Financial constraint: Maintaining on a lower dose costs less. For semaglutide, the NovoCare flat rate ($349/month) applies at all doses — a lower maintenance dose doesn't reduce cost. For tirzepatide via LillyDirect, pricing is dose-tier: 2.5 mg and 5 mg at $299/month vs $399–449/month at higher doses. A patient at 5 mg maintenance saves $100–150/month versus maintenance at 7.5 mg+.

Tolerability: Some patients have persistent GI side effects at their maximum therapeutic dose that are acceptable for an active weight-loss phase but not sustainable indefinitely. Stepping down to a lower dose may reduce tolerability burden while maintaining substantial benefit.

Transition point: Patients who have achieved their weight-loss goal and want to preserve the results without continuing at full therapeutic dose. The maintenance dose becomes the long-term management level.

Practical implementation

The dose step-down process mirrors the step-up titration but in reverse: reduce by one dose level, hold for 4–8 weeks to observe how weight, appetite, and side effects respond, then either maintain that level or step down further if needed.

The minimum effective maintenance dose is individual — some patients maintain well at a lower dose than others. Regular weight monitoring (weekly or biweekly) is the signal for whether the chosen maintenance level is holding.

Discuss the maintenance dose approach with your prescriber before any dose change. For T2D patients, dose reduction affects glycaemic control and requires coordinated management.

Editorial note: This article awaits medical-reviewer signoff. Dose decisions — including maintenance dose levels — are clinical decisions made with your prescriber based on your individual response, metabolic goals, and medical history.